|Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease|
|Du Yipeng; Wang Wei; Yang Wei; He Bei|
|关键词||interleukins pulmonary disease chronic obstructive anti-inflammatory agents, interleukin 32 protein human|
|刊名||CHINESE MEDICAL JOURNAL|
|WOS标题词||Science & Technology|
|类目[WOS]||Medicine, General & Internal|
|研究领域[WOS]||General & Internal Medicine|
|关键词[WOS]||AIRWAY INFLAMMATION ; KAPPA-B ; COPD ; CYTOKINE ; IL-32 ; SPUTUM ; ASSOCIATION ; EMPHYSEMA ; ASTHMA|
Background The interleukin (IL)-32/tumor necrosis factor (TNF) alpha pathway is supposed to play a key role in the amplification of the immune response in chronic obstructive pulmonary disease (COPD) inflammation. Inhaled corticosteroids (ICS) in combination with long-acting beta 2-agonists (LABA) have shown airway anti-inflammatory effects in recent studies, but the mechanism is still uncertain.
Methods Patients were treated in a randomized, open-labeled, parallel group clinical trial with either a combination of salmeterol xinafoate/fluticasone propionate (SF; Seretide, GlaxoSmithKline) Diskus (50/500 mu g twice daily) or ipratropium bromide/salbutamol (IS; Combivent, Boehringer Ingelheim) MDI (42 mu g/240 mu g quartic daily) for 12 weeks. At the start and the end of treatment, induced sputum was collected and the concentration of IL-32 and TNF-alpha, the number of neutrophils and eosinophils were measured.
Results Following 12 weeks of treatment, a statistically significant fall from baseline in the concentration of TNF-alpha in sputum (P=0.004) was seen after treatment with SF but not with IS. However, neither treatment had significant effects on the concentration of IL-32 in sputum. There was a decrease from baseline in the number of sputum neutrophils with SF that approached statistical significance (P=0.028) but not with IS, while the number of sputum eosinophils did not change significantly from baseline in either treatment group. There was a statistically significant decline from baseline in the quality of life as assessed by the St George′s respiratory questionnaire in both the SF (P=0.004) and IS (P=0.030) treatment groups, but no evidence of improvement in lung function was observed in either group.
Conclusion The sputum TNF-alpha and neutrophils, but not IL-32 and macrophages, could be reduced by ICS/LABA treatment, suggesting that IL-32 could be involved in the corticosteroid resistance of COPD inflammation.
|资助机构||National Natural Science Foundation of China|
|作者单位||Peking Univ, Hosp 3, Dept Resp Med, Beijing 100191, Peoples R China|
|Du Yipeng,Wang Wei,Yang Wei,et al. Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease[J]. CHINESE MEDICAL JOURNAL,2014,127(9):1613-1618.|
|APA||Du Yipeng,Wang Wei,Yang Wei,&He Bei.(2014).Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease.CHINESE MEDICAL JOURNAL,127(9),1613-1618.|
|MLA||Du Yipeng,et al."Interleukin-32, not reduced by salmeterol/fluticasone propionate in smokers with chronic obstructive pulmonary disease".CHINESE MEDICAL JOURNAL 127.9(2014):1613-1618.|